论文部分内容阅读
人骨保护素(osteoprotegerin.OPG)为一种破骨细胞抑制因子,其对破骨细胞的形成、分化和调节骨吸收的具有重要作用,骨保护素的研究在骨质疏松、骨硬化病、类风湿性关节炎、骨肿瘤、心血管疾病等临床疾病的发病机制及治疗方面均取得了较大进展。目前国外已经进行重组骨保护素治疗绝经后骨质疏松的临床试验,未发现明显毒性作用。本文对重组骨保护素-卡介苗的构建及防治骨质疏松症的研究进展发展前景进行了展望。
Osteoprotegerin (OPG), an osteoclast inhibitor, plays an important role in the formation and differentiation of osteoclasts and in the regulation of bone resorption. Osteoprotegerin has been studied in osteoporosis, osteopetrosis, Rheumatoid arthritis, bone tumors, cardiovascular diseases and other clinical pathogenesis and treatment have made great progress. At present, foreign countries have conducted clinical trials of recombinant osteoprotegerin in the treatment of postmenopausal osteoporosis, and no obvious toxic effect was found. In this paper, we prospected the development of recombinant osteoprotegerin-BCG and the development of osteoporosis prevention and treatment.